Terms: = Endocrine gland cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Treatment
65 results:
1. Value of diffusion kurtosis MR imaging and conventional diffusion weighed imaging for evaluating response to first-line chemotherapy in unresectable pancreatic cancer.
Zhang Z; Zhang Y; Hu F; Xie T; Liu W; Xiang H; Li X; Chen L; Zhou Z
Cancer Imaging; 2024 Feb; 24(1):29. PubMed ID: 38409049
[TBL] [Abstract] [Full Text] [Related]
2. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract] [Full Text] [Related]
3. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
[No Abstract] [Full Text] [Related]
4. [Efficacy and feasibility of catheter-based adrenal ablation on Cushing's syndrome associated hypertension].
Yan ZC; Jiang N; Zhang HX; Zhou Q; Liu XL; Sun F; Yang RM; He HB; Zhao ZG; Zhu ZM
Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Nov; 51(11):1152-1159. PubMed ID: 37963750
[No Abstract] [Full Text] [Related]
5. Development and validation of a nomogram for risk of pulmonary metastasis in non-papillary thyroid carcinoma: A SEER-based study.
Li Y; Gao X; Guo T; Liu J
Medicine (Baltimore); 2023 Aug; 102(32):e34581. PubMed ID: 37565907
[TBL] [Abstract] [Full Text] [Related]
6. D898_E901
Porcelli T; Moccia M; De Stefano MA; Ambrosio R; Capoluongo E; Santoro M; Hadoux J; Schlumberger M; Carlomagno F; Salvatore D
JCO Precis Oncol; 2023 Aug; 7():e2300052. PubMed ID: 37535881
[TBL] [Abstract] [Full Text] [Related]
7.
Gupta N; Huang TT; Nair JR; An D; Zurcher G; Lampert EJ; McCoy A; Cimino-Mathews A; Swisher EM; Radke MR; Lockwood CM; Reichel JB; Chiang CY; Wilson KM; Cheng KC; Nousome D; Lee JM
Sci Transl Med; 2023 Jun; 15(701):eadd7872. PubMed ID: 37343085
[TBL] [Abstract] [Full Text] [Related]
8. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract] [Full Text] [Related]
9. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A; Kutzera J; Geenen JJ; Pluim D; Hofland I; Sanders J; Lopez-Yurda M; Beijnen JH; Huitema ADR; Witteveen PO; Steeghs N; van Haaften G; van Vugt MATM; de Ridder J; Opdam FL
Gynecol Oncol; 2023 Jul; 174():239-246. PubMed ID: 37236033
[TBL] [Abstract] [Full Text] [Related]
10. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
Foster KI; Shaw KRM; Jin J; Westin SN; Yap TA; Glassman DM; Jazaeri AA; Rauh-Hain JA; Lee S; Fellman BM; Ju Z; Liu Y; Fleming ND; Sood AK
Cancer; 2023 Jun; 129(11):1672-1680. PubMed ID: 36930815
[TBL] [Abstract] [Full Text] [Related]
11. Amplified therapeutic targets in high-grade serous ovarian carcinoma - a review of the literature with quantitative appraisal.
Talbot T; Lu H; Aboagye EO
Cancer Gene Ther; 2023 Jul; 30(7):955-963. PubMed ID: 36804485
[TBL] [Abstract] [Full Text] [Related]
12. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring
Fu S; Yao S; Yuan Y; Previs RA; Elias AD; Carvajal RD; George TJ; Yuan Y; Yu L; Westin SN; Xing Y; Dumbrava EE; Karp DD; Piha-Paul SA; Tsimberidou AM; Ahnert JR; Takebe N; Lu K; Keyomarsi K; Meric-Bernstam F
J Clin Oncol; 2023 Mar; 41(9):1725-1734. PubMed ID: 36469840
[TBL] [Abstract] [Full Text] [Related]
13. ccne1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma.
Mei J; Tian H; Huang HS; Wu N; Liou YL; Chu TY; Wang J; Zhang W
Cell Cycle; 2023 Jan; 22(1):85-99. PubMed ID: 36004387
[TBL] [Abstract] [Full Text] [Related]
14. Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification.
Hollis RL; Meynert AM; Michie CO; Rye T; Churchman M; Hallas-Potts A; Croy I; McCluggage WG; Williams ARW; Bartos C; Iida Y; Okamoto A; Dougherty B; Barrett JC; March R; Matakidou A; Roxburgh P; Semple CA; Harkin DP; Kennedy R; Herrington CS; Gourley C
Clin Cancer Res; 2022 Aug; 28(16):3546-3556. PubMed ID: 35696721
[TBL] [Abstract] [Full Text] [Related]
15. ccne1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Gallo D; Young JTF; Fourtounis J; Martino G; Álvarez-Quilón A; Bernier C; Duffy NM; Papp R; Roulston A; Stocco R; Szychowski J; Veloso A; Alam H; Baruah PS; Fortin AB; Bowlan J; Chaudhary N; Desjardins J; Dietrich E; Fournier S; Fugère-Desjardins C; Goullet de Rugy T; Leclaire ME; Liu B; Bhaskaran V; Mamane Y; Melo H; Nicolas O; Singhania A; Szilard RK; Tkáč J; Yin SY; Morris SJ; Zinda M; Marshall CG; Durocher D
Nature; 2022 Apr; 604(7907):749-756. PubMed ID: 35444283
[TBL] [Abstract] [Full Text] [Related]
16. PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells.
Oliveira HA; Bueno AC; Pugliesi RS; da Silva Júnior RMP; de Castro M; Martins CS
J Endocrinol Invest; 2022 May; 45(5):999-1009. PubMed ID: 34988938
[TBL] [Abstract] [Full Text] [Related]
17. [Retrospective study of thyroid invasion and central lymph node metastasis in 124 patients with hypopharyngeal carcinoma].
Liu HF; Huang ZG; Fang JG; Chen XH; Zhang Y; Hou LZ; Ma HZ; Guo W; Zhong Q
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 Sep; 56(9):956-961. PubMed ID: 34666444
[No Abstract] [Full Text] [Related]
18. WEE1i-ATRi combination therapy: a promising low-dose treatment for
Goehring L; Huang TT
Cell Rep Med; 2021 Sep; 2(9):100402. PubMed ID: 34622238
[No Abstract] [Full Text] [Related]
19. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
Moskovich D; Finkelshtein Y; Alfandari A; Rosemarin A; Lifschytz T; Weisz A; Mondal S; Ungati H; Katzav A; Kidron D; Mugesh G; Ellis M; Lerer B; Ashur-Fabian O
Oncogene; 2021 Nov; 40(44):6248-6257. PubMed ID: 34556811
[TBL] [Abstract] [Full Text] [Related]
20. Changes in natural killer cell activity after surgery and predictors of its recovery-failure.
Kim EY; Hong TH
J Surg Oncol; 2021 Dec; 124(8):1561-1568. PubMed ID: 34351633
[TBL] [Abstract] [Full Text] [Related]
[Next]
